Cristina Z.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase II Open‑Label Study of Cemiplimab Plus Platinum‑Gemcitabine in Treatment‑Naïve Advanced Squamous NSCLC Selected by Low Cytidine Deaminase Activity
- Efficacy of Durvalumab and Tremelimumab as Consolidation Therapy in Limited Stage Small-Cell Lung Cancer Post-Concurrent Chemoradiation Therapy
Data & Insights
Has run more than one trial at 59 of 256 partner sites.
Specializations
Genitourinary Oncology
Clinical activity is centered on urothelial carcinoma, bladder cancer, and renal cell carcinoma, including advanced, metastatic, and unresectable disease. The portfolio also includes molecularly defined kidney cancer subtypes such as clear cell renal cell carcinoma and papillary renal cell carcinoma.
- Metastatic urothelial cancer
- Advanced renal cell carcinoma
- Muscle-invasive bladder cancer
- MET-driven renal tumors
Work in this area reflects strong involvement in targeted therapy and immuno-oncology for genitourinary malignancies.
Hematologic Malignancies
Research interest extends across multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma, and other B-cell lymphomas. The clinical landscape also includes high-risk and relapsed or refractory blood cancers.
- Relapsed/refractory multiple myeloma
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Follicular lymphoma
- Diffuse large B-cell lymphoma
Therapeutic focus includes monoclonal antibodies, BCL-2 inhibition, BTK inhibition, and combination approaches in lymphoid and plasma cell disorders.
Thoracic and Breast Oncology
Clinical work covers non-small cell lung cancer, small-cell lung cancer, and breast cancer, including advanced, metastatic, and biomarker-defined populations. Interest also includes HER2-negative and hormone receptor-positive breast cancer as well as EGFR-mutated lung cancer.
- Advanced non-small cell lung cancer
- Limited-stage small-cell lung cancer
- Hormone receptor-positive breast cancer
- EGFR mutation-positive lung cancer
This area highlights involvement in immune checkpoint inhibition, targeted therapy, and treatment strategies for biomarker-selected solid tumors.
Prostate and Hormone-Driven Cancers
Research activity includes metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and other hormone-responsive malignancies. The scope also reaches endocrine-sensitive breast cancer and related endocrine treatment settings.
- Metastatic castration-resistant prostate cancer
- Metastatic castration-sensitive prostate cancer
- Hormone receptor-positive advanced breast cancer
- Endocrine therapy-sensitive disease
The therapeutic emphasis is on androgen receptor pathway strategies and endocrine-based treatment in advanced disease.
Rare and Complex Systemic Diseases
The broader research profile includes myelofibrosis, chronic myeloid leukemia, Parkinson’s disease, and selected cardiovascular and renal conditions. These studies span both oncologic and non-oncologic therapeutic domains.
- Myelofibrosis
- Chronic myeloid leukemia
- Parkinson’s disease
- Atherosclerotic cardiovascular disease
Clinical interests also extend to supportive care and organ-protective therapies in complex hospitalized and chronic disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.